News
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
1File photo: Novo (company)
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced
In South China Morning Post’s words.2
Background: Novo (company)
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.3
The story so far
One source so far- Reports
- 1
- Newsrooms and sources
- 1
- Last 3 hours
- 0
Only one newsroom has this so far.
The numbers behind it
How it spread, where it’s heading and where the coverage is from
Every report, in order
1 reports from 1 newsrooms, first to latest. Each links to the original.
South China Morning PostIn this story
Connected stories
More like this
- Novo Nordisk says Wegovy pill to cost up to $395 per month
Australian Financial Review
- Judge, top silk scoop up Firmus shares
Australian Financial Review
- Can you please find me a job?
The Sydney Morning Herald
